Latest Eisai Co. Ltd. Stories
Tokyo, Sept 29, 2010 - (JCN Newswire) - Eisai Co., Ltd. and Shinshu University venture company Anaeropharma Science, Inc.
Tokyo, Sept 30, 2010 - (JCN Newswire) - Brain Factory Co., Ltd. and Eisai Co., Ltd. announced today that they have concluded a license agreement concerning a dihydrogen phosphonoxy methoxy derivative of ravuconazole (ravuconazole prodrug).
Tokyo, Sept 7, 2010 - (JCN Newswire) - SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd.
Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease.
Tokyo, Aug 24, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today that results of a Phase III study in epilepsy patients with refractory partial seizures demonstrate the clinical benefits of the novel investigational compound E2007 (generic name: perampanel).
EXTON, Pa., Sept.
EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc.
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S.
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd.
- A poem in which the author retracts something said in an earlier poem.